Sign Out
As with other sulphonylureas, there is possibility of the following events: Nervous System Disorders: Headache, tremor have been reported in patients treated with glipizide GITS.
Gastrointestinal Disorders: Abdominal pain, nausea, constipation, diarrhea, epigastric discomfort and vomiting.
Blood and Lymphatic System Disorders: Leucopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia and pancytopenia.
Hepatobiliary Disorders: Cholestatic jaundice, toxic hepatitis and hepatic porphyria. Discontinue treatment if cholestatic jaundice occurs. Hepatic porphyria has been reported with sulfonylureas.
Investigations: Occasional mild to moderate elevations of SGOT, LDH, alkaline phosphatase, BUN and creatinine. The relationship to glipizide is uncertain.
Metabolism and Nutrition Disorders: Hypoglycemia may be severe, prolonged and may result in coma. Hyponatremia has been reported. Disulfiram-like reactions have been reported with sulfonylureas.
Psychiatric Disorders: Confusion (this is usually transient and does not require discontinuation of therapy; however, it may also be a symptom of hypoglycemia).
Skin and Subcutaneous Tissue Disorders: Allergic skin reactions including mucocutaneous, eruptions, pruritus, urticaria, maculopapular eruptions.
Eye Disorders: Visual disturbances eg, blurred vision and decreased vision have been reported in patients treated with glipizide GITS.
